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medically refractory, unrelenting severe neuropathic pain that ruins their quality of life and productivity. For
this group, neurosurgery can offer two different kinds of neuromodulation that may help: deep brain simulation
(DBS) and motor cortex stimulation (MCS). Unfortunately, there is no consensus on how to perform these
procedures, which stimulation parameters to select, how to measure success, and which patients may beneﬁt.
This brief review highlights the literature supporting each technique and attempts to provide some comparisons
and contrasts between DBS and MCS for the treatment of neuropathic pain. Finally, we highlight the current
unanswered questions in the ﬁeld and suggest future research strategies that may advance the care of our
patients with neuropathic pain.
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Neuropathic pain remains a public health concern. The neurosurgi-
cal treatment of neuropathic pain has been hindered by i) ambiguity
in its diagnosis, ii) small experiences in many different centres, iii)
lack of evidence based guidelines, and iv) and the fact that it can be
very difﬁcult to treat. This brief review was invited by the organizing
committee of the 2nd International Conference on Deep Brain Stimula-
tion held in Dusseldorf March 15–16, 2016 and was designed to sum-
marize and compare the relevant literature supporting deep braintreet, Health Sciences Centre,
ney).
on behalf of the ResearchNetwork ofstimulation (DBS) andmotor cortex stimulation (MCS) for treating neu-
ropathic pain. Ultimately, there are no prospective, randomized, con-
trolled trials comparing DBS and MCS for neuropathic pain — so the
reader will be left, once again, to choose what they think is best for
their patients. This review may provide some guidance for that choice.
This paper will provide a brief background for this discussion and
then will summarize the literature supporting DBS and MCS and ﬁnally
draw some comparisons between the two techniques.2. Background
Neuropathic pain has been deﬁned as “pain arising as direct conse-
quence of a lesion or disease affecting the somatosensory system.” [1]Computational and Structural Biotechnology. This is an open access article under the CC BY
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believe that one procedure will be superior (or even successful) for all
conditions. Indeed, this is the ﬁrst serious problem with our current
literature. Many studies have ‘lumped’ patients with different types of
neuropathic pain together when discussing outcomes. This increases
the number of patients treated but dilutes the results for any one
condition. It is quite clear that the neuropathic pain in an amputated
limb is very different from the pain in a limb that has been amputated
following a plexus avulsion. Although the patients may look the same
with an amputated limb and may describe their pain similarly as the
worst pain imaginable, constant and burning, the neurophysiology
underpinning their pain is different (peripheral nerve versus spinal
cord injury) and their response to neuromodulation appears to be
different (better response following peripheral nerve injury). Because
there are so many different kinds of neuropathic pain, it is not
uncommon for any one neurosurgical centre to have experience with
only a few patients of each subtype. This is the second serious problem
with our current literature. Only a few centres have a large experience
with a single, well-deﬁned subtype of pain. This review will try to
categorize the response to DBS or MCS based on pain subtype rather
than make sweeping conclusions concerning ‘neuropathic pain’.
Deep brain stimulation has been used for neuropathic pain for over
50 years and similarly, motor cortex stimulation has been used for
over 30 years. Despite this long time, there is no consensus on how
these operations should be performed. Each neurosurgical centre may
have unique differences in surgical technique that could profoundly
alter outcome. Most obviously, DBS has been used to stimulate a variety
of brain targets for pain relief including the following: septal area (of
historical signiﬁcance and not included in this review), sensory thala-
mus (the majority of reports), periaqueductal grey or periventricular
area, and more recently the anterior cingulate cortex. What is less
obvious but equally important is there are no guidelines on post-
operative stimulation parameters. It has recently become clear to our
group that slight differences in stimulation parameters following MCS
can have profound effects on pain outcome [2]. This is the third serious
problemwith our current literature. There is no consensus on operative
technique or post-operative stimulation parameters.
Finally, there is no agreement on how we should evaluate these
techniques. If an operation completely alleviates pain in 25% of patients,
is it ‘successful’ or a ‘failure’. To an investigator evaluating the technique
it may seem an unreliable failure but to the small cohort of patients
whose unrelenting pain is gone — it is a blessing. This is the fourth
problem with our current literature, we have not agreed how to evalu-
ate these operations. Is any improvement worthwhile or is a 50% pain
reduction in at least half the patients required to be deemed successful?
3. Deep brain stimulation
DBS was ﬁrst reported for the treatment of nociceptive pain in 1954
[3]. By the 1970s, many specialized centres were using DBS to treat
neuropathic pain. Despite its widespread use for neuropathic pain,
only a dozen large series have been published [4]. In the last decade,
only eight series with more than six patients have been published.
During all that time, only two randomized controlled studies were
published. The ﬁrst, by Marchand et al. [5], reported that placebo
stimulation improved pain intensity in a blinded setting whereas
thalamic stimulation did not. The second, by Fontaine et al. [6], dealt
with cluster headache not neuropathic pain.
The early excitement supportingDBS for painwas dampened by two
industry-supported, open label studies that failed to reach their deﬁned
targets for success [7]. The ﬁrst trial, sponsored by Medtronic, was
powered to demonstrate that at least half of patients internalized
would get 50% pain relief. Between 1989 and 1993, 196 patients were
enrolled. Those who did not get initial beneﬁt from the implanted elec-
trode during a trial period were not included because their implantable
neural stimulator (INS) was not internalized. The trial failed to reachoutcome. A second trial, also sponsored by Medtronic, began in 1992
but failed because of lack of accrual by 1998. Without prospective data
to support DBS for pain, the Food and Drug Administration in the
United States has not allowed its use except as an ‘off label’ device [7].
The few large, open label trials reporting on the outcome of DBS for
pain have all suggested the technique is beneﬁcial. Rasche et al. reported
56 patients treated for a variety of neuropathic pain syndromes with a
follow up of between 1 to 8 years [8]. Electrodes were implanted in
the sensory thalamus and the periventricular grey region and evaluated
alone or in combination in a blinded fashion prior to implantation of the
stimulator. The best long-term results were obtained in patients with
failed back surgery syndrome (FBSS) andneuropathic pain of peripheral
origin (also known as CRPS-II). Poor results were seen following central
pain due to spinal cord injury or post-stroke pain. In the CRPS-II group,
four out of six patients had more than a 50% reduction in pain.
Boccard et al. reported the long-term outcome of 59 patients with
DBS in the sensory thalamus, periventricular grey, or both for a variety
of neuropathic conditions [9]. After a mean follow-up of almost
20 months, pain was compared to pre-operative levels ‘using a general
linear mixedmodel’. For patients with phantom limb 8/9 improved; for
brachial plexus injury 3/6 improved; for post-stroke pain 16/23
improved; for spinal cord injury 4/7 improved; and for cephalalgia 6/
11 improved. Improvement was deﬁned as a global improvement of
their EuroQol-5D (for the patients that improved, pain reduced by 50%
on a visual analogue scale).
Kumar et al. reported the outcome of DBS in the periventricular/
periaqueductal grey area (n=49) or sensory thalamus/internal capsule
(n = 16) for a variety of neuropathic pain syndromes [10]. Patients
were followed for at least 6 months, mean follow-up was 78 months
and success deﬁned as greater than 50% reduction in visual analogue
pain scores. For the patients with FBSS, 32/43 had long-term improve-
ment; for peripheral neuropathy 3/5 improved; for thalamic pain 1/5
improved; for trigeminal neuropathy 4/4 improved; for spinal cord
injury 0/3; for post-herpetic neuralgia 0/3; and for phantom limb pain
1/1 improved.
These studies have some consistent ﬁndings. First, DBS is effective
for FBSS. This indication should be reserved for patients who have failed
the less invasive spinal cord stimulation (aswas theprotocol for the trial
by Rasche et al). Second, DBS is effective for neuropathic pain of periph-
eral origin. Third, DBS is poor (but not universally ineffective) for the
treatment of pain following spinal cord injury or stroke. Fourth, initial
beneﬁt may be lost after several years.
4. Motor cortex stimulation
Since its introduction by Tsubakawa in 1991, Motor Cortex Stimula-
tion (MCS) has been used for a variety of neuropathic pain syndromes
[11]. Initially used for thalamic pain, it has been tried for many
treatment-resistant pain syndromes such as phantom limb pain,
postherpetic neuralgia, brachial plexus avulsion, poststroke pain,
Wallenberg syndrome, complex regional pain syndrome, pain second-
ary to multiple sclerosis, spinal cord injury pain, and posttraumatic
brain injury pain [12].
Fontaine et al. summarized the literature up to 2006. In summary, a
greater than 40% improvement in pain scores were reported in 54% of
117 patients with central pain and 68% of 44 patients with trigeminal
neuropathic pain [13]. A recurrent theme appears that MCS is effective
for deafferentation pain due to peripheral (phantom limb or trigeminal
nerve injury) or central causes (post-stroke). It appears to be much less
effective for spinal cord injury pain, post-herpetic neuralgia, or plexus
avulsion.
Monsalve reviewed the literature concerningMCS and facial chronic
neuropathic pain (an amalgamation of conditions causing neuropathic
facial pain) [12]. He found 84% of 100 patients implanted following a
trial had at least 40% pain improvement. Lefaucher et al. reported a ran-
domized control trial of MCS for peripheral neuropathic pain where 13
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the device was ‘on’ compared to ‘off’ [14]. This signiﬁcance was lost,
however, once statistically corrected for multiple comparisons. Nguyen
et al. reported a randomized, blinded crossover trial of MCS in 10
patients with neuropathic pain with signiﬁcant reduction in pain
when the device ‘on’ compared to ‘off’ [15]. Of note, there was a poor
response in patients with hemibody post-stroke pain and post-
herpetic neuralgia. Velasco et al. reported a randomized trial of MCS
(some patients were simultaneously reported in the Nguyen paper)
and found a similar beneﬁt of MCS in a prospective, blinded trial.
Again, several patients (2/5) with post-herpetic neuralgia had no
beneﬁt [16]. Velasco et al. also reported that four of ﬁve patients with
complex regional pain syndrome improved their pain, sensory and
sympathetic symptoms in a blinded trial of MCS [17].
These studies had some consistent ﬁndings. First, MCS appears to be
very effective for deafferentation facial pain. Second, MCS appears to be
effective in post-stroke pain. Third, authors often commented (anecdot-
ally) that MCS was not effective for lower limb pain or pain in an area
where there was motor weakness.
Two trials have not shown efﬁcacywithMCS but both suffered from
methodological ﬂaws. Radic et al. reported that half their twelve
patients dropped out of the study and the remaining ‘treatment’ group
received what we would consider was subtherapeutic stimulation
time (10min ‘on’ and 120min ‘off’) [18]. Our preliminary (unpublished)
data fromanongoing prospective, randomized trial ofMCSwith varying
time of stimulation has shown that most patients lose the beneﬁt of
stimulation once the ‘on’ time is reduced below 50%. Sachs et al.
retrospectively reported that only 14% of 14 patients had long term
pain relief [19]. Within the cohort, ﬁve patients had no motor response
to stimulation (a ﬁnding some would consider a contraindication to
MCS [20]), three had lower limb pain (known to be difﬁcult to treat
with MCS [13]) and their stimulation protocol used 30 min ‘wash-out’
(whereas patients blinded to settings usually take three days to notice
a difference [2]).
5. A comparison of DBS and MCS for neuropathic pain
There is very little data providing a direct comparison between these
two techniques. Katayama et al. reported no difference between MCS
and thalamic DBS for phantom limb pain [21]. The same group reported
the effects of spinal cord stimulation (SCS), thalamic DBS andMCS in 45
patients with post-stroke pain. Satisfactory pain control was obtained
more frequently as the stimulation site was moved to higher levels
(7% by SCS, 25% by DBS and 48% by MCS) [22]. Nandi et al. reported
their experience with treating post-stroke pain with MCS and DBS
[23]. Only 1/6 patients had long-term beneﬁt following MCS (although
none were trialled) whereas 2/2 patients had longer-term beneﬁt
following DBS of the periventricular grey region (4 were trialled). Son
et al. recently published a direct comparison of MCS or thalamic DBS
in the same eight patientswith neuropathic pain [24].MCSwas success-
ful in reducing pain in 6/8 and DBS was successful in 2/8. The improved
rate of response and potentially reduced invasiveness led this group to
recommendMCS. It is of note that the reported beneﬁts in the individual
patients with spinal cord injury were 12.5%, 22%, 37.5% and unavailable.
The beneﬁts for the four post stroke patients were all more than 40%.
One obvious difference between the two techniques is that
placement of the DBS lead is inherentlymore invasive than the epidural
(or even subdural) MCS electrode.
6. Conclusions and direction for future research
Severe neuropathic pain remains a devastating condition. Upwards
of 5% of the population may be suffering moderate, medically intracta-
ble pain [25]. There are some patients in whom the pain is excruciating
and refractory to all medications. For this small cohort, neurosurgery
remains their only hope.Our ﬁeld needs evidence based guidelines for each of the neuropath-
ic pain conditions. In the past, most open label case series have ‘lumped’
many different conditions together and then made generalized
statements that a speciﬁc operation is effective for neuropathic pain. It
has become clear that each of the different pain syndromes may
respond differently to neuromodulation. Phantom limb pain, for
example, responses more favourably to neuromodulation than brachial
plexus avulsion pain. Trigeminal deafferentation pain responds very
favourably to neuromodulation whereas facial post-herpetic neuralgia
does not. Future trials need to have pure cohorts with only one
condition examined at a time. This will require multi-centre collabora-
tion in order to gain the necessary power for analysis. Collaboration
will require standardization of technique. This will be easy for the sur-
gery but the post-operative stimulation parameters are equally, if not
more, important. Our group has recently published evidence showing
that stimulation voltage changes as small as 10% can dramatically alter
pain modulation [2]. The very nature of DBS and MCS may allow for
blinded evaluation. We recommend future trials incorporate a post-
operative phase to optimize stimulation parameters and then a blinded
cross-over phase to test the response followed by an open label phase to
assess long-term efﬁcacy.
An exciting area of research is the pre-selection of patients using
repetitive transcranial magnetic stimulation (rTMS). This non invasive
method to stimulate the motor cortex has been shown to predict the
beneﬁcial effects of chronic MCS [26,27]. Finally, the Oxford group
continues to lead the ﬁeld with research into understanding the pain
pathways and clinical trials utilizing DBS in new areas — the anterior
cingulum [28]. The early results suggest this target may be able to
salvage patients who have failed earlier neuromodulation.
Ultimately, we hope there will be a reliable method of neuro-
modulation (either MCS or DBS) for each of the neuropathic pain
conditionswith a predictable response rate andminimal complications.
The joy and frustration of neurosurgery is captured succinctly in the
management of these patients with neuropathic pain.References
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